EditorÐThe interesting article 1 on the effect of temperature on brain tissue partial pressure of oxygen appears to be methodologically¯awed. A predictable, physically determined relationship between tissue PO 2 and temperature is shown that is expected from basic physical principles, and not from exacerbation of a pathophysiological process.
The aim of this observational study by Gupta and colleagues was to determine the effect of a reduction in brain parenchymal temperature on brain tissue PO 2 . This is an important question to answer, and the investigators correctly measured brain temperature directly and did not infer it from body temperature measurements. The Paratrend 7 (Diametrics Medical, High Wycombe, UK) was used to measure both systemic arterial and brain tissue PO 2 , PCO 2 , pH and temperature. Patient clinical management was according to a standard cerebral perfusion pressure procedure, but hypothermia was induced if intracranial pressure became refractory to medical interventions.
In summary, the results show that brain tissue PO 2 decreased with temperature, as did brain PCO 2 and arterial PCO 2 . Brain and arterial pH were not affected by a reduction in temperature and jugular venous saturation increased, with wide con®dence intervals at the lowest temperatures. Arterial PO 2 increased by up to 2 kPa with temperature. No indication of FI O 2 changes are given in the paper and an FI O 2 /Pa O 2 ratio would have permitted more informed analysis.
To understand the results, the readers require information on how the Paratrend 7 processes the measured variables. This monitor measures its variables using the pH stat method, where pH, PCO 2 and PO 2 are measured at the local temperature and not corrected to 37°C (information on PCO 2 and pH analysis is given in the text; PO 2 processing information from Diametrics Medical, by personal communication). Charles's Law states that, at a constant volume, the pressure of gas varies directly with absolute temperature. Therefore, a predictable, physically determined relationship, between brain tissue PO 2 and temperature is shown.
Conclusions that could be reached from this paper are therefore, that the predicted physical relationship between temperature and partial pressure are observed for PCO 2 and PO 2 . This is further supported by the very small 95% con®dence intervals, which, if attributable to a biological process, would be expected to show much greater variability. Such a pattern is seen in the jugular venous oxyhaemoglobin saturation data, as cerebral oxygen extraction is a biological process. Finally, using alpha stat processing, the opposite effect has been reported in 18 patients with severe traumatic brain injury who were treated with mild hypothermia within 20 h of injury. Mild hypothermia resulted in the mean (SD) brain tissue PO 2 increasing from 9.6 (6.8) mm Hg to 28.7 (8.8) mm Hg, and this change remained within this range for 3 days. 2 The changes reported in PCO 2 and PO 2 by Gupta and colleagues, at the lowest temperature range, could be attributable to changes in FI O 2 and mechanical ventilation. These data, therefore, neither support nor refute the value of hypothermia after traumatic brain injury.
P. Andrews Edinburgh, UK
EditorÐThank you for the opportunity to respond to the letter from Dr Andrews regarding our article. 1 He highlights some important principles regarding brain tissue gas monitoring with hypothermia.
Dr Andrews is correct in his statement that the tissue sensor (Paratrend 7) measures at local temperature and not corrected to 37°C (alpha stat mechanism and not pH stat, contrary to that stated in his letter). Although it is not clear whether Dr Andrews is arguing in favour of the pH stat method, this would be counterintuitive, as it is more clinically relevant to have tissue measurements at actual brain temperature and not relative to a temperature of 37°C. In addition, studies have demonstrated that the alpha stat method of measurement applies more appropriately during hypothermia. 3 Dr Andrews is correct in his recount of Charles's Law. However, if the ®ndings in our study were a predictable response according to Charles's Law as he suggested, then we should have seen a linear change in brain oxygen tension with temperature. This clearly is not the case. A non-linear decrease in brain tissue oxygen below 35°C is demonstrated in the results. Therefore these ®ndings are unlikely to be attributable to Charles's Law alone. The observation that brain tissue oxygen tension decreases despite a rise in arterial oxygen content as temperature is reduced, further refutes Dr Andrews' hypothesis that this is a predictable physical change.
Although no information regarding FI O 2 was given in the manuscript, FI O 2 was altered to maintain a target Pa O 2 according to our unit protocol. The Pa O 2 and brain tissue oxygen data is presented in the paper, and I fail to see how the FI O 2 relationship has any useful bearing on the results.
Finally, Dr Andrews quotes a recent paper from the Chinese Journal of Traumatology, 2 which demonstrated a rise in brain tissue oxygen tension after induced hypothermia, occurring 24 h after injury in pooled data from 18 patients with severe head injury. The temporal pro®le of an increase in tissue oxygen tension after 24 h has been documented in patients with severe head injury, because of well recognized changes in cerebral blood ow. The observation of the rise in tissue oxygen with hypothermia may therefore be attributable to predictable changes in pathophysiology within the ®rst 24 h of injury, and not because of induced hypothermia. This would also explain the very low mean value of brain tissue oxygen found in the Chinese study within the ®rst 24 h. We did not study patients within the ®rst 24 h of injury, and tissue oxygen tension was higher in our patients before induction of hypothermia. It is also not clear from this paper as to whether the tissue oxygen results are controlled for cerebral perfusion pressure or Pa CO 2 , which was the case in our study. There are a number of other differences and shortfalls in the Chinese paper, and I therefore do not think that the results of the two studies are comparable.
Whilst we do not claim that our study should alter clinical practice as yet, we do suggest that our ®ndings require further investigation to determine whether induced hypothermia should be targeted to a more limited temperature range. Whilst Dr Andrews raises some interesting questions regarding the methodology, I do not think that his conclusions are supported by the data presented in our paper. Evaluation of platelet aggregation in¯ow and platelet aggregometry during pregnancy
EditorÐI read with interest the paper by Vincelot and colleagues. 1 The authors presented the PFA â (platelet function analyser) as a device giving reproducible results similar to an in vitro aggregation test. This is not the case. The PFA â was designed to assess platelet-related haemostasis as whole blood¯ows under high shear rate conditions. 2 Brie¯y, the system consists of a disposable test cartridge in which citrated whole blood is aspirated through a capillary and the microscopic aperture cut in a membrane that had been coated with either collagen and ADP, or collagen and epinephrine. The instrument determines the time required for occlusion of the aperture (closure time). The test is sensitive to abnormalities in platelet adhesion and aggregation occurring under high shear rate conditions, similar to those encountered in a stenotic blood vessel (5000±6000 s ±1 ). The molecular mechanism evaluated in this system, initial binding of von Willebrand factor (vWF) by GPIb followed by GPIIb/IIIa-dependent binding of vWF, is different from that of ®brinogen-mediated platelet aggregation. At the low shear rates associated with the stirred suspensions of platelets used in aggregometers (shear rate <100 s ±1 ) ®brinogen predominates over vWF in driving aggregation by binding to GPIIb/IIIa. 3 However, at very high shear rates, ®brinogen is no longer ef®cient at mediating aggregation, whereas vWF can bind to GPIb and GPIIb/IIIa. 4 This distinction may be important because it has been reported that antibodies directed against GPIb, GPIIb/IIIa and vWF prolong the PFA â closure time, whereas anti®brinogen antibodies do not affect it. 5 In contrast, in the absence of ®brinogen, platelet-rich plasma failed to support aggregation. 6 Nevertheless, we now know that the clinical sensitivity and speci®city of the PFA â in healthy subjects are no different from aggregometry. 7 
M. Fattorutto Brussels, Belgium
EditorÐThank you for the opportunity to answer Dr Fattorutto's comments. He clearly poses the question of which test, if any, is able to evaluate platelet performance during the coagulation process, and what is its clinical signi®cance. His approach suggests that there are clear cut differences in the pathways of platelet aggregation: either ®brinogen-dependant (under low shear rates conditions), or pathways dependant on vWF, GPIb, GPIIb/ IIIa interaction (under high shear rates). Such a dichotomy is of interest in understanding the biological mechanisms of in vitro platelet aggregation. But it is probably a simpli®ed approach of what is happening clinically in vivo, as well as in vitro, compared with the use of more global biological tests such as the PFA-100 system or thrombelastography. Although the PFA-100 was designed primarily to evaluate platelet function during high shear rate conditions, it is also used on whole blood without excluding or modifying (as in platelet aggregometry) the in vivo natural environment of platelets, such as erythrocytes and plasma.
Pregnancy is a unique situation for which the PFA-100 may be useful to evaluate platelet competence. In women with pregnancyinduced thrombocytopenia, ®brinogen levels are increased and thus the evaluation of platelet defects is less dependent on ®brinogen. In pre-eclamptic patients, the alteration in platelet function is more complex, and depends on the reduction of circulating platelet number and function. This alteration in function is not unique to pre-eclampsia. In most pregnant patients, an increase in ADP-induced platelet aggregation with increased ATP secretion is observed. 8±9 In more severe cases of preeclampsia, however, the decrease in collagen, ADP or epinephrine-induced platelet aggregation results from a depletion of platelet content and from the effects of associated disseminated intravascular coagulation. 10±11 Use of PFA-100 in such circumstances, using the same agonists as the platelet aggregation test, is thus of interest, but remains to be proven. The PFA-100 needs to be validated by comparison with aggregation tests, and its use in predicting the risk of haemorrhage needs to be demonstrated before recommending its use. Until now, no test of platelet function has been able to do so.
N. Nathan A. Julia Limoges, France
